Plus Therapeutics develops diagnostic tests and targeted radiation treatments for cancers of the central nervous system. It last closed at $0.63 on Nov 17, down 10.60% on the day. The average 12-month price target from 2 analysts is $37.00 (+5770.2% from the last close), with a high of $43.00 and a low of $31.00.
Only 2 firms rated CNSY in the past 90 days, not enough for a consensus
Average 12-month target
$37.00
▲ 5770.2% upside
Based on 2 analysts who set a price target on CNSY in the past 90 days. The average target is $37.00, with a high of $43.00 and a low of $31.00, compared with the last close of $0.63.
Low $31.00Avg $37.00High $43.00
Blue marker: last close $0.63
Highest target$43.00
Average target$37.00
Lowest target$31.00
Latest rating changes
Lake StreetMaintained
Oct 1Buy$31
Ascendiant CapitalMaintained
Sep 11Buy$43
Date
Firm
Action
Rating
Price target
Oct 1
Lake Street
Maintained
Buy
$31
Sep 11
Ascendiant Capital
Maintained
Buy
$43
Loading…
Whale Options Flow
90D
No whale options trades in CNSY in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CNSY is in one of them and how their past CNSY trades turned out.
Plus Therapeutics is a U.S. healthcare company based in Houston, Texas, that develops precision diagnostic tests and targeted radiopharmaceutical treatments for cancers of the central nervous system. Its CNSide Test is a laboratory developed test that identifies cancer cells spread to the brain and spinal fluid in patients with carcinomas and melanomas, and it is offered through national insurance agreements. Its lead drug candidate, rhenium (186Re) obisbemeda, is designed to deliver radiation directly into brain tumors such as recurrent glioblastoma and leptomeningeal metastases. The company is also developing a second radiotherapy candidate for liver cancers.